KR0177519B1 - 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용 - Google Patents

세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용 Download PDF

Info

Publication number
KR0177519B1
KR0177519B1 KR1019910701072A KR910701072A KR0177519B1 KR 0177519 B1 KR0177519 B1 KR 0177519B1 KR 1019910701072 A KR1019910701072 A KR 1019910701072A KR 910701072 A KR910701072 A KR 910701072A KR 0177519 B1 KR0177519 B1 KR 0177519B1
Authority
KR
South Korea
Prior art keywords
icam
asthma
therapeutic agent
glycoproteins
airway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019910701072A
Other languages
English (en)
Korean (ko)
Other versions
KR920700667A (ko
Inventor
디. 웨그너 크레이그
에이취. 군델 로버트
로스레인 로버트
Original Assignee
데이비드 이. 프랭크 하우저
베링거 인겔하임 파머수티칼 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이비드 이. 프랭크 하우저, 베링거 인겔하임 파머수티칼 인코오포레이티드 filed Critical 데이비드 이. 프랭크 하우저
Publication of KR920700667A publication Critical patent/KR920700667A/ko
Application granted granted Critical
Publication of KR0177519B1 publication Critical patent/KR0177519B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019910701072A 1989-03-09 1990-03-09 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용 Expired - Lifetime KR0177519B1 (ko)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US32123989A 1989-03-09 1989-03-09
US32101889A 1989-03-09 1989-03-09
US32123789A 1989-03-09 1989-03-09
US321,018 1989-03-09
US321,239 1989-03-09
US321,237 1989-03-09
US321,237. 1989-03-09
US321,239. 1989-03-09
US32448189A 1989-03-16 1989-03-16
US324,481 1989-03-16
US324,481. 1989-03-16
US40140989A 1989-09-01 1989-09-01
US401,409. 1989-09-01
US401,409 1989-09-01

Publications (2)

Publication Number Publication Date
KR920700667A KR920700667A (ko) 1992-08-10
KR0177519B1 true KR0177519B1 (ko) 1999-03-20

Family

ID=27541038

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701072A Expired - Lifetime KR0177519B1 (ko) 1989-03-09 1990-03-09 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용

Country Status (13)

Country Link
EP (1) EP0387701B1 (enExample)
JP (1) JP3119483B2 (enExample)
KR (1) KR0177519B1 (enExample)
AT (1) ATE79270T1 (enExample)
AU (1) AU638450B2 (enExample)
CA (1) CA2047721C (enExample)
DE (1) DE69000248T2 (enExample)
DK (1) DK0387701T3 (enExample)
ES (1) ES2035668T3 (enExample)
GR (1) GR3006073T3 (enExample)
HU (1) HU216313B (enExample)
NZ (1) NZ232868A (enExample)
WO (1) WO1990010453A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
DE68929096T2 (de) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
EP0468257B1 (en) * 1990-07-20 1999-09-01 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
AU8765391A (en) * 1990-10-03 1992-04-28 Boehringer Ingelheim Pharmaceuticals, Inc. Method for treating inflammation using anti-idiotypic antibodies
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
ES2094837T3 (es) * 1991-04-03 1997-02-01 Boehringer Ingelheim Pharma Metodo para inhibir la toxicidad pulmonar por oxigeno.
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
JPH06502195A (ja) * 1991-07-31 1994-03-10 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 内皮性白血球粘着分子−１およびそれに対する抗体の喘息治療における使用
JPH07502727A (ja) * 1991-10-01 1995-03-23 ザ・ジエネラル・ホスピタル・コーポレーシヨン 接着分子に対する抗体を用いた同種移植片拒絶の防止
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
RU94046450A (ru) * 1992-06-22 1996-10-10 Майлз Инк. (US) Мультимерная icam-i, способ усиления связывания icam-i с лигандом, фармацевтическая композиция, способ индукции декансидации, способ необратимого ингибирования заражения клеток
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
CA2454358A1 (en) 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Also Published As

Publication number Publication date
WO1990010453A1 (en) 1990-09-20
EP0387701A1 (en) 1990-09-19
DK0387701T3 (da) 1992-12-07
HU216313B (hu) 1999-06-28
ES2035668T3 (es) 1993-04-16
KR920700667A (ko) 1992-08-10
NZ232868A (en) 1995-05-26
JP3119483B2 (ja) 2000-12-18
ATE79270T1 (de) 1992-08-15
HU902883D0 (en) 1991-12-30
CA2047721C (en) 2004-01-06
CA2047721A1 (en) 1990-09-10
AU638450B2 (en) 1993-07-01
AU5349990A (en) 1990-10-09
EP0387701B1 (en) 1992-08-12
DE69000248D1 (de) 1992-09-17
JPH04504127A (ja) 1992-07-23
GR3006073T3 (enExample) 1993-06-21
DE69000248T2 (de) 1993-01-07
HUT65843A (en) 1994-07-28

Similar Documents

Publication Publication Date Title
KR0177519B1 (ko) 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용
US5730983A (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
US7666432B2 (en) Methods of suppressing fibrosis and fibrocyte formation
US8187608B2 (en) Treatment of Fibrosis related disorders
JP3288042B2 (ja) 細胞間接着分子−３およびその結合リガンド
JP3166854B2 (ja) 細胞間粘着分子の官能性誘導体を用いた抗ウィルス剤
DK175491B1 (da) Anvendelse af ICAM-1 og dets funktionelle derivater til behandling af ikke-specifik inflammation
JP4590152B2 (ja) 喘息の処置
JPH05503070A (ja) 新規の細胞外基質レセプター／リガンド相互作用を利用した血管内皮に対するリンパ球接着の抑止方法
WO1993006842A1 (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
US6797270B1 (en) Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
EP2507266B1 (en) TREATMENT OF IgE-MEDIATED DISEASE
US20090035321A1 (en) Intercellular adhesion molecules and their binding ligands
AU665232C (en) Treatment for asthma
Bhatia FcγRIIIa: Tissue distribution and regulation of expression
Banerjee Specific Spatio-Temporal Interplay of Cell Movement defines Asthma Pathogenesis
Gomer et al. Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
JPH06145199A (ja) Ｉｃａｍ−１のｍａｃ−１結合部位
MXPA96004715A (en) Use of agents that block the molecular interaction / receiver adhesion interaction in the treatment of viral infections respirator

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19910909

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950309

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19910909

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980223

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980829

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19981118

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19981118

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20011019

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20021021

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20031030

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20041029

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20051028

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20061031

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20071026

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20081027

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20091116

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20101109

Start annual number: 13

End annual number: 13

PR1001 Payment of annual fee

Payment date: 20111115

Start annual number: 14

End annual number: 14

FPAY Annual fee payment

Payment date: 20121109

Year of fee payment: 15

PR1001 Payment of annual fee

Payment date: 20121109

Start annual number: 15

End annual number: 15

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20140518

Termination category: Expiration of duration